Xenopat in Colorectal Cancer Trial with Alzheimer’s Drug
Alzheimer’s Drug Shows Promise in Colorectal Cancer Treatment Research
Table of Contents
- Alzheimer’s Drug Shows Promise in Colorectal Cancer Treatment Research
- alzheimer’s Drug Shows Promise in Colorectal Cancer Research: Your Questions Answered
- What is the central focus of the research discussed in this article?
- Which company is leading this research?
- What is Xenopat investigating in relation to this Alzheimer’s drug and colorectal cancer?
- What is the role of Neuro-Bio in this research?
- How is the research funded?
- What is the purpose of the funding?
- When was Xenopat founded, and what is its background?
- What does Xenopat specialize in?
- What other research does Xenopat Conduct?
- Which researcher joined the Xenopat team for this project?
- What is the T14 peptide and why is it relevant?
- Where does the information in this article come from?
- Can we expect immediate breakthroughs from this research?
- How manny researchers are currently working at Xenopat?
- What is metastasis in cancer?
- Can you summarize the key aspects of this research in a table?
BARCELONA — A Catalan company, Xenopat, has contributed too research exploring the potential of an Alzheimer’s drug in treating colorectal cancer, the Generalitat announced Sunday.
Collaboration Focuses on Metastasis Inhibition
Xenopat partnered with British pharmaceutical firm Neuro-Bio to investigate whether the drug’s ability to inhibit the T14 peptide – a marker of Alzheimer’s when present at elevated levels – could also halt metastasis in colorectal cancer.
Funding Boosts Research Efforts
Xenopat,which specializes in preclinical studies of oncological medicine efficacy and toxicity,received 135,640 euros through the TechniosPring Industry program. The grant, co-financed with the European Commission, supports the hiring of researchers for business research and development and technological transfer, according to the Generalitat.
Xenopat’s Background and Expansion
Founded in 2014 as a spinoff of Idibell, ICO, and bellvitge University Hospital, Xenopat employs a team of eight.The company conducts research for pharmaceutical companies and research centers both domestically and internationally.
Researcher Hired for Project
For this specific project, Xenopat hired Dr. Raquel Buqué, a specialist in Biomedicine, as a researcher. Dr. Buqué has since joined the company’s team permanently following the project’s completion.
alzheimer’s Drug Shows Promise in Colorectal Cancer Research: Your Questions Answered
What is the central focus of the research discussed in this article?
The article highlights research exploring the potential of an Alzheimer’s drug to treat colorectal cancer. Specifically, the research, led by a Catalan company named Xenopat, investigates the drug’s ability to inhibit metastasis in colorectal cancer cells.
Which company is leading this research?
The primary company mentioned as leading this research is Xenopat, a catalan company specializing in preclinical studies of oncological medicines.
What is Xenopat investigating in relation to this Alzheimer’s drug and colorectal cancer?
Xenopat is investigating whether an Alzheimer’s drug can halt metastasis in colorectal cancer. They’re focusing on the drug’s ability to inhibit the T14 peptide, a marker associated with Alzheimer’s when elevated, and testing if this same mechanism can prevent the spread of cancer cells.
What is the role of Neuro-Bio in this research?
Xenopat partnered with the british pharmaceutical firm Neuro-Bio.neuro-Bio likely provided the Alzheimer’s drug or contributed to the scientific understanding of its mechanisms.
How is the research funded?
xenopat received a grant of 135,640 euros through the Techniospring Industry program.This grant is co-financed by the European Commission.
What is the purpose of the funding?
The funding primarily supports the hiring of researchers for business research and development, and also technological transfer.
When was Xenopat founded, and what is its background?
Founded in 2014, Xenopat is a spin-off of Idibell, ICO and Bellvitge University Hospital.
What does Xenopat specialize in?
Xenopat specializes in preclinical studies related to the efficacy and toxicity of oncological medicines. They work with pharmaceutical companies and research centers domestically (in Spain) and internationally.
What other research does Xenopat Conduct?
The provided text does not detail other research Xenopat specifically conducts.
Which researcher joined the Xenopat team for this project?
Dr. Raquel Buqué, a specialist in Biomedicine, was hired as a researcher for this specific project.She has as joined the company’s team permanently after the project’s completion.
What is the T14 peptide and why is it relevant?
The T14 peptide is a marker of Alzheimer’s disease when it’s present at elevated levels. the research is investigating whether inhibiting this same peptide could also stop metastasis in colorectal cancer.
Where does the information in this article come from?
The information originates from an announcement made public by the Generalitat and other sources mentioned in the article.
Can we expect immediate breakthroughs from this research?
The article does not detail whether breakthroughs are possible, the nature of the research is still preliminary. Additional research will be needed to determine concrete results.
How manny researchers are currently working at Xenopat?
Xenopat employs a team of eight researchers.
What is metastasis in cancer?
Metastasis refers to the spread of cancer cells from the primary tumor to other parts of the body.
Can you summarize the key aspects of this research in a table?
certainly. Here’s a summary:
| Aspect | Details |
|---|---|
| Research Focus | potential of an Alzheimer’s drug for treating colorectal cancer by inhibiting metastasis. |
| Lead Company | Xenopat (Catalan company) |
| Partner Company | Neuro-Bio (British pharmaceutical firm) |
| Target | Inhibition of the T14 peptide, a marker associated with Alzheimer’s and also investigated as a potential target for metastasis. |
| Funding Source | Techniospring Industry Program (co-financed by the European Commission) |
| Funding Amount | 135,640 euros |
| Research Goal | To assess if the Alzheimer’s drug can prevent the spread of colorectal cancer. |
| Key Researcher | Dr. Raquel Buqué (specialist in Biomedicine) was hired for the project. |